Advanced Search
Contact | Corporate | Help

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Sponsors:
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
  • Brigham and Women's Hospital
  • Eli Lilly and Company
  • Sanofi-Synthelabo
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Female
Names:
  • Drug: Gemcitabine
  • Drug: Oxaliplatin
  • Drug: Bevacizumab
Enrollment:
40

Additional information about NCT00418093.


SourceSolution © 2008-2012